FDA panel rejects REMS proposal for long-acting opioids
September 15th 2010FDA advisory committee members voted 25 to 10 to reject a proposed plan to establish a risk evaluation and mitigation strategy for extended-release and long-acting opioid analgesics during the joint meeting on July 23 of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee in Adelphi, Md.
Local pharmacists: Serving their communities
September 15th 2010Patients often bring their own set of challenges with them to the pharmacy counter and community pharmacists have taken notice. Many have responded by creating programs that not only help patients secure the medication they need, but also offer them ways to make the most of their treatment plans.
Plavix biomarker test can improve patient outcomes
September 15th 2010In a novel collaboration with PBM giant CVS Caremark and its specialty pharmacy Generation Health, PGXL Laboratories will use its expertise in anticoagulants to improve the quality of patient care through pharmacogenetic testing, physician education, and drug-specific software programs.
State deals setback in drive to end pharmacy ownership restrictions in North Dakota
August 17th 2010The North Dakota secretary of state rejected thousands of signatures from a petition that would have put a measure on the November ballot to end the state?s restrictions on pharmacy ownership, the Associated Press reported.
FDA approves longer Valcyte therapy for CMV disease in adult kidney-transplant patients
August 17th 2010FDA approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney-transplant patients at high risk for cytomegalovirus (CMV) disease, according to an Aug. 10 statement made by Genentech Inc.
Hospital-acquired MRSA infections decline between 2005 and 2008
August 17th 2010Infections with the deadly methicillin-resistant Staphylococcus aureus (MRSA) bacteria contracted in hospitals and other healthcare settings have declined 28% over a 4-year period, according to a new Centers for Disease Control and Prevention (CDC) study of about 15 million people.
Novartis Vaccines begins shipment of seasonal influenza vaccine
August 17th 2010Novartis Vaccines has started shipping the FDA-approved seasonal influenza vaccine Fluvirin to U.S. customers ahead of the 2010&endash;2011 season, allowing healthcare practitioners to initiate protection of their patients well in advance.
FDA issues warning on stolen Advair Diskus inhalers
August 17th 2010Certain lots of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhalers that were stolen from a GlaxoSmithKline (GSK) distribution warehouse near Richmond, Va., in August 2009 have recently been found in some pharmacies, according to FDA.
FDA approves 3-in-1 combination drug for high blood pressure
August 17th 2010FDA has approved Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide), a new three-in-one combination product taken once daily for the treatment of hypertension in patients who are not adequately controlled on any 2 of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers, and diuretics, according to Daiichi Sankyo Inc.
Newer AEDs linked to self-harm, suicidal behavior
August 17th 2010Patients taking newer antiepileptic drugs (AEDs) that are associated with a high risk of depression may have an elevated risk of self-harm or suicidal behavior, but other groups of AEDs do not appear to carry the same risk, according to research published in the July 27 issue of Neurology and reported in HealthDay News.
OAD agents effective in reducing hemoglobin levels up to 1.5%
August 17th 2010Oral antidiabetic (OAD) agents generally result in a maximum 1.5% drop in hemoglobin (Hb) A1C levels, with sulfonylureas and thiazolidinediones having a slightly more beneficial effect than other classes of oral agents, according to research published in the August issue of Diabetes Care and reported by HealthDay News.
Naltrexone, bupropion combination helps individuals lose excess weight
August 17th 2010Investigational combination treatment with sustained-release (SR) naltrexone and bupropion (Contrave, Orexigen Therapeutics) combined with lifestyle modification, appears effective in helping people lose 5% or more of their excess body weight, according to research published online July 30 in The Lancet and reported by HealthDay News.